Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy

Bone Marrow Transplantation volume 53, pages 1589–1592 (2018)Cite this article

Subjects

To the editor: Multiple myeloma (MM) is a clonal B-cell disorder of terminally differentiated plasma cells that account for 1% of all malignancies in the United States [1]. Over the past two decades, overall survival (OS) has improved from an age-adjusted 5-year relative survival of 35.6% in 1998–2001 to 44% in 2006–2009 [2]. This is largely due to increased use of autologous hematopoietic cell transplantation (AHCT) and the introduction of modern therapies [3,4,5]. In the current era, modern combination therapies yield overall response rates (ORRs) of nearly 100% and complete response (CR) rates of 30–50% [6] for patients with newly diagnosed MM (NDMM).

Attainment of CR either in the pre- or post-AHCT period predicts improved progression-free survival (PFS) and OS [7,8,9]. Despite deep responses, the vast majority of patients eventually relapse due to persistent low levels of disease undetectable by traditional measurements [10]. This underscores the need for more sensitive measures of minimal residual disease (MRD) in order to risk stratify patients and to inform for clinical decision making.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 2016;51:479–91.

    Article  CAS  Google Scholar 

  2. Pulte D, Redaniel MT, Lowry L, Bird J, Jeffreys M. Age disparities in survival from lymphoma and myeloma: a comparison between US and England. Br J Haematol. 2014;165:824–31.

    Article  Google Scholar 

  3. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063–73.

    Article  CAS  Google Scholar 

  4. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

    Article  CAS  Google Scholar 

  5. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

    Article  CAS  Google Scholar 

  6. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–86.

    Article  CAS  Google Scholar 

  7. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399–406.

    Article  Google Scholar 

  8. Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775–82.

    Article  Google Scholar 

  9. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025–31.

    Article  CAS  Google Scholar 

  10. Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant. 2016;51:2–12.

    Article  CAS  Google Scholar 

  11. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360–76.

    Article  Google Scholar 

  12. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:78–88.

    Article  Google Scholar 

  13. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  Google Scholar 

  14. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119:687–91.

    Article  CAS  Google Scholar 

  15. Avet-Loiseau H, Lauwers-Cances V, Corre J, Moreau P, Attal M, Munshi N. Minimal residual disease in multiple myeloma: final analysis of the IFM2009 Trial. Blood. 2017;130:435.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    C. Amos Clark, Michael Byrne, Wichai Chinratanalab, Brian G. Engelhardt, Stacey A. Goodman, Shelton L. Harrell, Adetola A. Kassim, Bipin N. Savani, Salyka Sengsayadeth, Madan Jagasia & R. Frank Cornell

  2. Department of Hematopathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Claudio A. Mosse

  3. Division of Biostatistics and Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Heidi Chen

Authors
  1. C. Amos Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudio A. Mosse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heidi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wichai Chinratanalab
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brian G. Engelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stacey A. Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shelton L. Harrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Adetola A. Kassim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bipin N. Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Salyka Sengsayadeth
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Madan Jagasia
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R. Frank Cornell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Frank Cornell.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clark, C.A., Mosse, C.A., Chen, H. et al. Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. Bone Marrow Transplant 53, 1589–1592 (2018). https://doi.org/10.1038/s41409-018-0241-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0241-2

Search

Advanced search

Quick links